Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 566 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vaginal Diseases Clear all

Conditions: Infertility
Interventions: INVOcell device, Traditional IVF; Device · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 37 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Vaginal Health
Interventions: Once Daily Women's Probiotic, Placebo; Dietary Supplement · Other
Lead sponsor: Garden of Life, LLC; Industry
Eligibility: 19 Years to 70 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Wellington, Florida

Conditions: Vulvovaginal Candidiasis
Interventions: NDV-3A, NDV-3, Placebo; Biological
Lead sponsor: NovaDigm Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more

Conditions: Bacterial Vaginosis
Interventions: Metronidazole oral tablets 500mg, 1% SPL7013 Gel, Placebo gel; Drug
Lead sponsor: Starpharma Pty Ltd; Industry
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 37
States / cities: Birmingham, Alabama • Montgomery, Alabama • Little Rock, Arkansas + 32 more

Conditions: Bacterial Vaginosis
Interventions: Lactobacillus crispatus CTV-05, Metronidazole, Placebo; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: San Diego, California • San Francisco, California • Chicago, Illinois + 1 more

Conditions: Vaginal Douching, Bacterial Vaginosis
Interventions: Brief, motivational interviewing intervention; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 16 Years to 24 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Endometrial Cancer, Cervical Cancer, Vaginal Stricture, Radiation Toxicity
Interventions: Silicone Dilator, Standard Dilator; Device
Lead sponsor: Margaret Liotta; Other
Eligibility: 18 Years and older · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Cervical Cancer, Endometrial Cancer, Leukemia, Non-Hodgkin's Lymphoma, Uterine Cancer, Vaginal Cancer, Infertility
Interventions: survey instrument; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: BACTERIAL VAGINOSIS
Interventions: RIFAXIMIN VAGINAL TABLET 25 MG, RIFAXIMIN VAGINAL TABLET 100 MG, PLACEBO VAGINAL TABLET, METROGEL VAGINAL; Drug
Lead sponsor: Alfasigma S.p.A.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cancer
Interventions: protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy; Genetic · Other · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 120 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Vulvovaginitis, Vaginitis
Interventions: clindamycin phosphate/butoconazole nitrate, clindamycin phosphate, butoconazole nitrate; Drug
Lead sponsor: Lumara Health, Inc.; Industry
Eligibility: 16 Years and older · Female only
Enrollment: 1,443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 81
States / cities: Birmingham, Alabama • Enterprise, Alabama • Chandler, Arizona + 69 more

Conditions: Bacterial Vaginosis
Interventions: LACTIN-V, Placebo control substance; Drug
Lead sponsor: Osel, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Graft Vs Host Disease, Vulvovaginal Signs and Symptoms
Interventions: Vulvovaginal Symptom Questionnaire, Vaginal Microbiome Evaluation; Other · Diagnostic Test
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV Infections
Interventions: Vehicle gel formulations; Drug
Lead sponsor: Biosyn; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV/AIDS, Menopause, Inflammation Vagina
Interventions: Tenofovir, Emtricitabine; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bacterial Vaginosis
Interventions: GoldenCare, Metronidazole; Drug
Lead sponsor: CDA Research Group, Inc.; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 2
States / cities: Detroit, Michigan • Philadelphia, Pennsylvania

Conditions: Vaginismus
Interventions: BOTOX; Biological
Lead sponsor: Plastic Surgery Professional Association; Other
Eligibility: 20 Years to 40 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Manchester, New Hampshire

Conditions: Vaginitis, Dyspareunia, Breast Neoplasms
Interventions: Testosterone propionate; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Pawtucket, Rhode Island • Burlington, Vermont

Conditions: Atrophic Vaginitis
Interventions: Film forming silicone gel (7-0940); Device
Lead sponsor: Stratpharma AG; Industry
Eligibility: Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital, Vulvovaginal Candidiasis (VVC)
Interventions: Boric acid, Placebo; Drug · Other
Lead sponsor: pH-D Feminine Health LLC; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 26
States / cities: Mobile, Alabama • Little Rock, Arkansas • Huntington Park, California + 20 more

Conditions: Candidiasis, Vulvovaginal
Interventions: OCF001 Intravaginal Gel, Placebo Gel; Drug
Lead sponsor: Sano Chemicals Inc; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Endometrial Carcinoma, Endometrial Endometrioid Adenocarcinoma, Female Reproductive System Neoplasm, Stage II Ovarian Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: Behavioral Intervention, Educational Intervention, Internet-Based Intervention, Interview, Survey Administration, Virtual Technology Intervention; Behavioral · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 12
States / cities: Arcadia, California • Duarte, California • Irvine, California + 8 more

Conditions: Breast Cancer, Vaginal Dryness, Dyspareunia, Sexual Health Quality of Life
Interventions: Testosterone; Drug
Lead sponsor: Creighton University; Other
Eligibility: 50 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Vaginal Bleeding
Interventions: Intrauterine system; Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Morristown, New Jersey • Newark, New Jersey

Search by objective public record fields.

Comparing Intra-vaginal Culture of Embryos to In-vitro Culture of Embryos With Minimal Stimulation

Garden of Life Once Daily Women's Probiotic: Vaginal pH and Quality of Life Study

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)

LACTIN-V Study for Recurrent Bacterial Vaginosis

Brief, Behavioral Intervention to Reduce Douching Among Adolescent and Young Women

An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis

Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance

Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

Vaginal Infection Study

Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis

Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation

An Imaging Trial of the Distribution of Topical Gel Formulations in the Human Vagina

Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine Disposition in Female Genital Tract

GoldenCareTM for the Treatment of Bacterial Vaginosis

Botox Injection for Treatment of Vaginismus

Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.

An Innovative Silicone Wound Dressing for the Management of Atrophic Vaginitis

Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis

Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence

Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer

Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy

Does Skyla Insertion Timing Impact Bleeding?